BACKGROUND The aim of this trial was to compare healing (assessed by optical coherence tomography-OCT) of biolimus A9 and everolimus drug-eluting stents at 9-month follow-up in patients with ST-segment elevation myocardial infarction (STEMI) treated by primary PCI (pPCI). 9-month clinical and angiographic data were also compared in both groups.
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METHODS 201 patients with STEMI treated by primary PCI were randomly enrolled in the trial. 101 patients were randomized to the biolimus A9 stent group and 100 patients to the everolimus group. All patients were pre-treated with a standard therapy (unfractionated heparin, aspirin and clopidogrel). The use of inhibitors of GP IIb/IIIa and thrombus-aspiration were left at the discretion of physicians, however both were strongly recommended. Stent implantation was carried out according to the standard clinical practice employing low pressure stent deployment with high-pressure postdilatation using shorter, non-compliant balloon. All patients were scheduled for 9month clinical, angiographic and OCT follow-up. Primary end-point of this study were the number of uncovered struts.
RESULTS
All procedures were carried out without complications in both groups. Baseline demographic and procedural characteristic were well balanced in both groups. The rate of MACE did not differ significantly at 30 days between both groups. There was one acute stent thrombosis requiring immediate re-PCI in the everolimus stent group and one asymptomatic stent thrombosis in the biolimus group (revealed during stage PCI of non-culprit lesion). Furthermore, there was one non-cardiac death in the biolimus group. 9-month angiographic and OCT follow-up underwent 87% patients in everolimus and 90% patients in biolimus group respectively. At 9-month follow, the rate of MACE and angiographic restenosis were comparable and very low in both groups (2 vs. 1% and 1 vs 1% respectively; P¼NS). All in-segment and in-stent angiographic data (reference diameter, minimal diameter, mean diameter, % stenosis) were comparable at 9month in both groups. OCT data presents Table. The rate of uncovered struts were significantly higher in biolimus group (19.67AE16.52 vs. 9.99AE10.38; p¼0.0001). On the other hand, there was a trend to higher mean and minimal lumen diameter (3.35mmAE0.56 vs. 3.2mmAE0.43; p¼0.06 and 2.88mmAE0.55 vs. 2.74mmAE0.49; p¼0.09).
CONCLUSIONS At 9-month follow-up, second generation everolimus drug-eluting stent shows better healing when compared to biolimus second generation drug-eluting stent. However, the stent struts coverage is considerably high in both groups. BACKGROUND The Biolimus A9 coated Biofreedom stent is a polymer free stainless steel drug eluting stent. In an animal models 98% of the drug has diffused into the vessel wall in 1 month and it is reasonable to consider short term DAPT of 1 month for patients with this stent. Moreover, Biofreedom stent would be ideal in patients who may not tolerate 12 months of DAPT therapy. The aims of this study was to evaluate the indications, safety, efficacy and medium term outcome of real world patients who had PCI using Biofreedom stent and short term DAPT therapy.
METHODS The cardiac interventional center at the Royal Bournemouth Hospital, UK has been one of the leading recruiting centers in the world for the Biofreedom stent LEADERS Free trial. After the recruitment period was complete, open label Biofreedom stent was incorporated in selected PCI cases who had high risk of bleeding and would benefit from short term DAPT therapy. The indication for PCI, procedural details, images, equipment used, complications and follow up details were recorded and analyzed.
RESULTS From August 2014 -May 2015, 1690 stent cases were identified of which Biofreedom stent was used in 60 cases (3.6%). Mean age of these 60 was 76.6þ/-10.5 years, 41 (68%) were males. The indication for PCI was STEMI 4 (6.7%), Non-STEMI 18 (30%), unstable angina 5 (8.3%), stable angina 21 (35%) and staged procedure in 12 (20%) patients. Left ventricular systolic function was normal in 56.6%, mildly impaired 6.6%, moderately impaired 21.6% and severely impaired in 6.6%. A Biofreedom stent was selected during PCI in view of concomitant warfarin therapy in 27 (56.5%), elderly age 9 (15%), awaiting noncardiac surgery 8 (13.3%), anemia 3 (5%), bleeding issues 9 (15%) and due to poor compliance of medication in 4 (6.6%). Stent was deployed in LMS in 2, LAD 34, circumflex 17, RCA in 12 and 2 in venous graft. The lesion was predilated in 48 (80%) of cases and rotablation and laser atherectomy was performed prior to stent deployment in 8 (13.3%) and 3 (5%), respectively. The mean stent diameter was 3.08þ/-0.40mm and length 35.8þ/-18.8mm. No major complications was recorded during the stent deployment 1 month DAPT therapy was advised in 55 (91.6%), 6 months in 1 and 12 months in 4 patients. Patients were followed up for a period of 160þ/-84 days. Fifty three (88%) had a good medium term outcome. Five (8.3%) died during the follow up period (4 patients with either cardiogenic shock, ventilated primary PCI and VT). One patient each developed restenosis and subacute stent thrombosis (Biofreedom deployed after laser PCI for underexpanded stent).
CONCLUSIONS The use of very short term DAPT with the Biofreedom stent in patients at high risk of bleeding events was associated with event free survival of 88% within this small case series. When prolonged DAPT is contraindicated, Biofreedom offers an alternative solution to conventional DES and BACKGROUND Inflammation is well known as predictor of survival among patients with chronic kidney disease (CKD), and the CKD was reported as predictor of drug eluting stent (DES) stent failure. Assessment of inflammation may be helpful to understand mechanism of DES failure among CKD patients.
METHODS
We investigated consecutive 1238 patients who have available paired C-reactive protein (CRP) (pre-procedure as baseline and 8-12 months later PCI as late-phase) among patients undergoing DES implantation. CRP elevation was defined as >0.2mg/dl. We divided them into 5 groups according to CKD grade (G1-2: eGFR >60ml/min; n¼673, G3a:45-59 ml/min; n¼308, G3b: 30-44 ml/min; n¼118, G4: 29-15 ml/min; n¼34, G5: <15ml/min; n¼105), and investigated occurrence of major adverse cardiac event (MACE) comprised from all cause death, non-fetal myocardial infarction, target vessel revascularization, and any other unplanned revascularization.
